The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

Shane Crotty, David Maag, Jamie J. Arnold, +5

Nature Medicine

Viral ReplicationRna Virus MutagenMolecular BiologyVirologyVirus Gene +2

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

Sibylle Loibl, Joyce O’Shaughnessy, Michael Untch, +16

The Lancet Oncology

Breast OncologyParp Inhibitor VeliparibMedicinePharmacologyBreast Cancer +5

Inositol Pyrophosphates Inhibit Akt Signaling, Thereby Regulating Insulin Sensitivity and Weight Gain

Anutosh Chakraborty, Michael A. Koldobskiy, Nicholas T. Bello, +12

Cell

Metabolic SyndromeEnergy HomeostasisInsulin SignalingSignal TransductionMolecular Physiology +12

The Eukaryotic Translation Initiation Factors eIF1 and eIF1A Induce an Open Conformation of the 40S Ribosome

Lori A. Passmore, T.M. Schmeing, David Maag, +5

Molecular Cell

Protein BiosynthesisMolecular BiologyOpen ConformationEif1a InduceMedicine +2

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

Véronique Dièras, Hyo S. Han, Bella Kaufman, +19

The Lancet Oncology

Breast OncologyMedicinePharmacologyPathologyBreast Cancer +4

Hepatitis C Virus RNA-dependent RNA Polymerase (NS5B) as a Mediator of the Antiviral Activity of Ribavirin

David Maag, Christian Castro, Zhi Hong, +1

Journal of Biological Chemistry

Pi Release from eIF2, Not GTP Hydrolysis, Is the Step Controlled by Start-Site Selection during Eukaryotic Translation Initiation

Mikkel A. Algire, David Maag, Jon R. Lorsch

Molecular Cell

Start-site SelectionSystems BiologyProtein ExpressionNatural SciencesProtein Biosynthesis +6

Mechanistic Dissection of PARP1 Trapping and the Impact on <i>In Vivo</i> Tolerability and Efficacy of PARP Inhibitors

Todd A. Hopkins, Yan Shi, Luis E. Rodrı́guez, +11

Molecular Cancer Research

PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow

Todd A. Hopkins, William B. Ainsworth, Paul A. Ellis, +10

Molecular Cancer Research

The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex

Yupeng He, Sujatha Selvaraju, Michael L. Curtin, +34

Nature Chemical Biology

Protein FunctionSignal TransductionMolecular RegulationPrc2 ComplexMolecular Biology +5